Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15222963 | 0.85 | OPRM1 (0.46) | OPRM1OPRL1OPRD1OPRK1MEN1 | |
| Hydrochloric Acid SCHEMBL19990916 | 0.83 | OPRM1 (0.45) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL1310036 | 0.79 | CES1 (0.35) | OPRM1OPRD1OPRK1CES1 | |
| Trifluoroacetic Acid SCHEMBL1309725 | 0.79 | OPRM1 (0.40) | OPRM1OPRL1OPRD1OPRK1CES1 | |
| Trifluoroacetic Acid SCHEMBL31084021 | 0.78 | P2RY14 (0.35) | P2RY14OPRM1OPRL1 | |
| Trifluoroacetic Acid SCHEMBL1312432 | 0.78 | CYP2C9 (0.39) | OPRM1OPRL1OPRD1OPRK1MEN1 | |
| Trifluoroacetic Acid SCHEMBL31083969 | 0.77 | PKM (0.38) | P2RY14OPRM1OPRL1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL1310033 | 0.77 | OPRM1 (0.39) | OPRM1OPRL1OPRD1OPRK1CES1 | |
| Trifluoroacetic Acid SCHEMBL23467099 | 0.76 | SLC6A2 (0.41) | — | |
| SCHEMBL27846025 | 0.73 | ELANE (0.41) | OPRM1OPRD1OPRK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321257-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9868746-B2 | Substituted 5-aminothieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2817295-B1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170022216-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| US-9493481-B2 | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2817295-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013126856-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022216-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM5, CHRM4, CHRM3 | P2RY14 251/4885OPRM1 81/4885OPRL1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.